Leerink Partners Maintains Outperform on Tango Therapeutics, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 92.9%

Neg 0% Neu 0% Pos 92.9%

Leerink Partners analyst Andrew Berens maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $28 to $55.